Ongoing Study:

Phase 1b/2 Study of Annamycin in STS Lung Mets in Europe

Single-Center, Open-Label, Dose Escalation Study of Annamycin in Patients with Previously Treated Soft-Tissue Sarcomas (STS) with Pulmonary Metastases (ANNA-SARC) in Poland

Primary objective of the Phase 1B is to establish safety and tolerability of weekly dosed Annamycin in monotherapy in subjects with STS with lung mets and the Phase 2 portion is to determine the efficacy of Annamycin in subjects with STS with lung mets

Study Highlights:

Enrolling: Up to 64 subjects

Treatment period: 3 weeks on/1 week off 28-day cycle

Dose Escalation: First dose level of 35 mg/mescalating up to 100mg/m2

Primary Endpoint: Determine RP2D

Our Pipeline


Sign Up For Alerts